Table 5 Systemic chemotherapy for the patients with EHEs
Systemic chemotherapy regimen | No. | (%) | Individual response |
|---|---|---|---|
1st-line treatment | 10 | (100) | |
Carboplatin + paclitaxel + bevacizumab | 3 | PR, SD, PD | |
Paclitaxel | 2 | SD, SD | |
Pazopanib | 2 | SD, SD | |
Bevacizumab | 1 | SD | |
Streptozocin | 1 | NE | |
Cisplatin + epirubicin + bevacizumab | 1 | PD | |
2nd-line treatment | 4 | (40) | |
Carboplatin + pemetrexed + bevacizumab | 1 | PR | |
Thalidomide | 1 | PD | |
Irinotecan | 1 | SD | |
Interleukin-2 | 1 | SD | |
3rd-line treatment | 3 | (30) | |
Adriamycin | 1 | SD | |
Paclitaxel | 1 | SD | |
Pemetrexed + bevacizumab | 1 | SD | |
4th-line treatment | 1 | (10) | |
Investigational drug | 1 | SD | |
5th-line treatment | 1 | (10) | |
Investigational drug | 1 | SD |